Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12004770 | 0.93 | ALDH1A1 (0.49) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL15982318 | 0.93 | ALDH1A1 (0.49) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL2811174 | 0.93 | ALDH1A1 (0.49) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL25422192 | 0.93 | ALDH1A1 (0.49) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL28519312 | 0.93 | ALDH1A1 (0.49) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL1128242 | 0.89 | MEN1 (0.71) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL16749989 | 0.88 | HTT (0.46) | MEN1KMT2APOLBALDH1A1HTT | |
| SCHEMBL18840380 | 0.88 | ALDH1A1 (0.45) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL4656223 | 0.87 | ALDH1A1 (0.44) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL18286738 | 0.86 | ALDH1A1 (0.43) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270892-A1 | CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME | TRIUMF INC. (CA) | 2023-08-31 | — | — | US | disclosed |
| US-20230270892-A1 | CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME | TRIUMF INC. (CA) | 2023-08-31 | — | — | US | disclosed |
| EP-4110768-A1 | CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME | Triumf Inc. (CA) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270892-A1 | CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME | RAE1, TFRC, SLC30A6 | MEN1 214/4885KMT2A 2059/4885POLB 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.